Ketamine Plus Exposure Therapy For Post-Traumatic... — Clinical Trial Details

Phase I interventional

This is an open-label feasibility study to assess the acceptability of using combined oral ketamine (K) and prolonger exposure (PE) psychotherapy in patients with Post-Traumatic Stress Disorder. We hypothesize that treatment with oral ketamine in week 1 will reduce distress and fear in most participants, and make participation in PE during weeks 2-11 much easier. We anticipate that some patients completing K+PE will have complete resolution of their PTSD symptoms.

Male or female aged between 18 and 50 years
Capable of understanding and signing an informed consent
Diagnosed with post-traumatic stress disorder (PTSD) with a PSSI-5 score >23.
Patients must have had an inadequate response to prior treatment i.e. have not responded to at least two adequate trials of relevant medication and at least one trial of relevant psychotherapy.

Unknown facility — Australia

evidence of severe acute or chronic medical disorders,
past or current diagnoses of schizophrenia, bipolar disorder, or current psychotic symptoms
current diagnosis of severe personality disorder
female patients who are pregnant or lactating
drug abuse or dependence in the last 6 months
current significant suicidal ideation
participants must be free of recreational drug and alcohol use at the time of testing

Start: 2025-07-31

End: 2025-12-19

Company

Product

Legal

Ketamine Plus Exposure Therapy For Post-Traumatic Stress Disorder (PTSD)– Open Label Pilot Study Targeting Anxiety

Detailed Description

Study Arms & Interventions

Experimental Arm

Interventions

Participants

Inclusion Criteria

Locations

Exclusion Criteria

Study Details